Overview of Dr. Stieglitz
Dr. Elliot Stieglitz is a pediatric hematologist/oncologist in San Francisco, CA and is affiliated with multiple hospitals in the area, including UCSF Benioff Children's Hospital Oakland and Kaiser Permanente San Francisco Medical Center. He received his medical degree from Stony Brook University Health Sciences Center School of Medicine and has been in practice 9 years. He is one of 55 doctors at UCSF Benioff Children's Hospital Oakland and one of 25 doctors at Kaiser Permanente San Francisco Medical Center who specialize in Pediatric Hematology & Oncology. He also speaks multiple languages, including Spanish. He has more than 50 publications and over 500 citings.
Office
HDFCCC Stieglitz Lab
1450 3rd St, Room 283
San Francisco, CA 94158
Education & Training
University of California (San Francisco)Fellowship, Pediatric Hematology/Oncology, 2011 - 2014
New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2008 - 2011
Stony Brook University Health Sciences Center School of MedicineClass of 2008
Certifications & Licensure
CA State Medical License 2011 - 2026
NY State Medical License 2009 - 2012- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- K08 Clinical Investigator Award NHLBI @ NIH, 2017
- Individual Investigator Award American Cancer Society, 2016
- Rally Grant Rally Foundation for Childhood Cancer Research, 2016
- Join now to see all
Clinical Trials
- Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Start of enrollment: 2014 Mar 01
- Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Start of enrollment: 2018 Sep 09
- Expanded Access Program for Revumenib
Roles: Contact
Publications & Presentations
PubMed
- 98 citationsGenomic subtyping and therapeutic targeting of acute erythroleukemiaIlaria Iacobucci, Ji Wen, Manja Meggendorfer, John K. Choi, Lei Shi
Nature Genetics. 2019-03-29 - 33 citationsMEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.Peter M K de Blank, Andrea M Gross, Srivandana Akshintala, Jaishri O Blakeley, Gideon Bollag
Neuro-Oncology. 2022-11-02 - 7 citationsMatched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP ConsortiumYana Pikman, Sarah K. Tasian, Maria Luisa Sulis, Kristen E. Stevenson, Traci M. Blonquist
Cancer Discovery. 2021-06-01
Journal Articles
- Downregulating Notch Counteracts KrasG12D-Induced ERK Activation and Oxidative Phosphorylation in Myeloproliferative NeoplasmErik A Ranheim, David Yang, Warren S Pear, Lan Zhou, Mignon Loh, Eric Padron, Elliot Stieglitz, Nature
Abstracts/Posters
- DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical ImplementationElliot Stieglitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell MalignanciesElliot Stieglitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
- Promising New Combination of Drugs Identified to Treat Juvenile Myelomonocytic LeukemiaApril 7th, 2023
Baby Diagnosed with Rare Blood Cancer Saved by Miracle TreatmentSeptember 26th, 2019
Infant with Deadly Leukemia Saved by Drug for Adult Liver CancerSeptember 12th, 2019- Join now to see all
Other Languages
- Spanish
External Links
- LinkedInhttp://www.linkedin.com/pub/elliot-stieglitz/20/384/870
- Stieglitz Labhttps://www.stieglitzlab.com
- ElliotStieglitz.comhttp://www.elliotstieglitz.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
